Search results for "From ACP Journal Club"


 
Results 11 - 20 of about 131 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In types 1 and 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA1c at 26 wk

The arrival of once-weekly insulin will undoubtedly be welcomed by patients and clinicians, but the advantages of fewer shots will have to be weighed against less flexibility in dosing of basal insulin, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/07/14/7.htm
14 Jul 2023

KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/7.htm
12 May 2023

Some glucose-lowering drugs reduce HbA1c more than others

A recent meta-analysis supports the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in patients with diabetes and elevated cardiovascular risk, but cost remains a barrier, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/8.htm
11 Dec 2020

In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control

Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/10/08/7.htm
8 Oct 2021

In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality

The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/03/11/8.htm
11 Mar 2022

In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia

A reduction in hyperkalemia could allow use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or aldosterone-receptor blockers in at-risk patients, justifying the prescribing of sodium-glucose cotransporter 2 (SGLT2) inhibitors, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/09/16/6.htm
16 Sep 2022

In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y

Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/06/11/9.htm
11 Jun 2021

In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status

The combination of efficacy and safety data from a recent placebo-controlled trial and other research shows sodium-glucose cotransporter-2 inhibitors to be an important treatment for heart failure with preserved ejection fraction (HFpEF) regardless of patients' diabetes status, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2022/10/14/6.htm
14 Oct 2022

Glargine and liraglutide improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin, while liraglutide reduced CV events vs. glargine, glimepiride, or sitagliptin

Although microvascular complications and death were not materially different among the four treatment groups in a recent trial, the results do allow inferences about the role of sulfonylureas and dipeptidyl peptidase-4 inhibitors in practice, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/8.htm
13 Jan 2023

In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events

The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2018/06/08/7.htm
8 Jun 2018

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next